Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
7
Neutral
3
Bullish
4
Bearish
7
Neutral
3
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Tatva Chintan Pharma Chem Limited is a globally recognized specialty chemical manufacturer. Its core business lies in developing and distributing specialty chemicals like Phase Transfer Catalysts, Structure Directing Agents, and Electrolyte Salts.
In Q3 FY26, the company exhibited significant financial improvement with a 53% revenue growth from the previous year and a dramatic 10,889% increase in PAT.
Tatva Chintan's focus on 'green' chemistry, employing processes like electrolysis and continuous flow chemistry, underscores its commitment to sustainable practices.
The company benefits from a wide international reach, exporting over 62% of its products to countries including the USA, UK, and Germany.
Tatva Chintan's R&D capabilities are robust, with a DSIR-recognized facility and significant investments, facilitating innovative product development and process enhancements.
Chemicals & Petrochemicals
Specialty Chemicals
4,039 Cr
High Risk
77.1
44.1
0.1
5.2
1,786.70
977.85
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockTatva Chintan Pharma Chem Ltd (TATVA) is currently trading at 1,720.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Tatva Chintan Pharma Chem Limited is a globally recognized specialty chemical manufacturer. Its core business lies in developing and distributing specialty chemicals like Phase Transfer Catalysts, Structure Directing Agents, and Electrolyte Salts. In Q3 FY26, the company exhibited significant financial improvement with a 53% revenue growth from the previous year and a dramatic 10,889% increase in PAT. Tatva Chintan's focus on 'green' chemistry, employing processes like electrolysis and continuous flow chemistry, underscores its commitment to sustainable practices. The company benefits from a wide international reach, exporting over 62% of its products to countries including the USA, UK, and Germany. Tatva Chintan's R&D capabilities are robust, with a DSIR-recognized facility and significant investments, facilitating innovative product development and process enhancements.
Over the past 52 weeks, Tatva Chintan Pharma Chem Ltd has traded between a low of ₹977.85 and a high of ₹1,786.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Tatva Chintan Pharma Chem Ltd has a market capitalization of approximately 4,038.52. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Tatva Chintan Pharma Chem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 77.11 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,038.52 Cr, Tatva Chintan Pharma Chem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Tatva Chintan Pharma Chem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Tatva Chintan Pharma Chem Ltd is 77.11. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations for Q4 FY26 was INR 134.1 crore (INR 1,341 million), up 24% year-on-year and 2% quarter-on-quarter.
It is a directive issued by the Indian government under the Essential Commodities Act to manage and prioritize the distribution of natural gas due to disruptions in international LNG supply.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1157.00 | 5,018 Cr | 15.23 | 2.26 | 0.43 | 14.94 | 14.69 | 9.47 | ||
39.62 | 4,614 Cr | 37.73 | 5.23 | 0.06 | 12.32 | 17.29 | 12.78 | ||
2455.00 | 4,327 Cr | 23.40 | 3.17 | 2.20 | 13.38 | 12.68 | 7.51 | ||
633.20 | 4,254 Cr | 29.89 | 3.98 | 0.05 | 13.31 | 14.64 | 6.81 | ||
1720.20 | 4,039 Cr | 77.11 | 5.17 | 0.12 | 5.38 | 6.63 | 5.12 | ||
5035.00 | 3,807 Cr | 39.58 | 3.67 | 0.50 | 8.43 | 12.26 | 6.34 | ||
3030.00 | 3,701 Cr | 146.53 | 8.34 | 0.02 | 5.69 | 8.71 | 2.19 | ||
| Median: 7 Co. | — | 1720.20 | 4,254 Cr | 37.73 | 3.98 | 0.12 | 12.32 | 12.68 | 6.81 |
Regulatory/Compliance Filing
Tatva Chintan Pharma Chem Ltd to attend a one-to-one virtual analyst/investor meeting with Motilal Oswal AMC on 2026-07-31; no UPSI will be shared and discussion will rely on publicly available information.
Regulatory/Compliance Filing
Tatva Chintan Pharma Chem informs schedule of a one-to-one virtual analyst/investor meeting with Motilal Oswal AMC on 31 July 2026. No UPSI will be shared; discussion will use publicly available information.
Investor Presentation
Tatva Chintan Pharma Chem Ltd informed of a virtual one-to-one analyst/investor meeting with Ventura Securities on 30 July 2026; no UPSI will be shared.
Investor Presentation
Tatva Chintan Pharma Chem notifies a virtual one-to-one analyst/investor meeting with Ventura Securities on 30-07-2026; no UPSI will be shared and discussions will use public information.
Regulatory/Compliance Filing
Tatva Chintan Pharma Chem Ltd intimated a one-to-one virtual meeting with Tamohara Investment Managers on 30 July 2026. No UPSI will be shared; discussions will use publicly available information.
Regulatory/Compliance Filing
Tatva Chintan informs schedule of a one-to-one virtual analyst/investor meeting with Tamohara Investment Managers on 30-07-2026; no UPSI will be shared and only publicly available information will be discussed.
